Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relmada Therapeutics (RLMD) Change in Account Payables (2016 - 2026)

Relmada Therapeutics has reported Change in Account Payables over the past 3 years, most recently at $824.0 for Q1 2014.

  • Quarterly Change in Account Payables rose 224.66% to $824.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $20577.0 through Feb 2014, up 74.97% year-over-year, with the annual reading at -$2.6 million for FY2025, 510.15% down from the prior year.
  • Change in Account Payables was $824.0 for Q1 2014 at Relmada Therapeutics, down from $6665.0 in the prior quarter.
  • Over five years, Change in Account Payables peaked at $13749.0 in Q2 2013 and troughed at -$661.0 in Q1 2013.
  • The 3-year median for Change in Account Payables is $5667.0 (2012), against an average of $4714.0.
  • The largest YoY upside for Change in Account Payables was 7613.11% in 2013 against a maximum downside of 17.61% in 2013.
  • A 3-year view of Change in Account Payables shows it stood at $5667.0 in 2012, then increased by 17.61% to $6665.0 in 2013, then tumbled by 87.64% to $824.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Change in Account Payables are $824.0 (Q1 2014), $6665.0 (Q4 2013), and $13749.0 (Q2 2013).